PPARgamma targeted genome-based drug discovery; present and future direction

Hiroyuki Miyachi

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is known to regulate growth arrest and terminal differentiation of adipocytes initially, and glitazones are used as a new class of antidiabetic drugs clinically. Recent understanding of the functions of PPARs, using genome-wide analysis, as pleiotropic regulators of biological responses, including not only lipid, lipoprotein, glucose homeostasis, but also inflammation, differentiation and proliferation of various cancer cells, and memory, have provided an opportunity to develop novel PPARs ligands with characteristic subtype selectivity. Such ligands are not only chemical tools to investigate the functions of PPARs, but also candidates for the treatment of PPARs-mediated diseases. This article summarizes recent topics of the medicinal chemistry work on the design, synthesis and pharmacological evaluation of PPARs related agents.

Original languageEnglish
Pages (from-to)243-248
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Volume68
Issue number2
Publication statusPublished - Feb 2010
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'PPARgamma targeted genome-based drug discovery; present and future direction'. Together they form a unique fingerprint.

Cite this